Cunha Isabella de Souza, Silva Tayná Cristina da, Malluta Éverson Fernando, Scolaro Bruno Lorenzo, Velho Pablo Sebastian, Stall Juliane
UNIVALI, Unidade de Saúde da Família e Comunidade, Clínica Interdisciplinar de Doença Inflamatória Intestinal, Itajaí, SC, Brasil.
Arq Gastroenterol. 2020 Jan-Mar;57(1):69-73. doi: 10.1590/S0004-2803.202000000-12.
Patients with inflammatory bowel disease (IBD) vaccinated for hepatitis B have a low success rate in achieving protective antibody levels. The main factors suggested for this are IBD itself and the use of immunosuppressive drugs.
To evaluate the concentration of anti-HBs antibodies and to verify factors associated with the effectiveness of hepatitis B vaccination in patients with IBD.
This is a prospective, consecutive, observational, descriptive and analytical, non-randomized, qualitative study that evaluated the levels of anti-HBs antibodies in IBD patients at the Interdisciplinary Inflammatory Bowel Disease Clinic of the Family and Community Health Unit of UNIVALI - Itajaí, Santa Catarina.
Thirty-six patients were vaccinated against hepatitis B virus (HBV), of which 29 were female. The average age was 46.2 years. Regarding the type of IBD, twenty-four patients had Crohn's disease and the duration of inflammatory bowel disease was 74 months. Fifteen patients were on concomitant immunosuppressive therapy. The effective response rate to HBV vaccine was 72.2%, verified by anti-HBs titration ≥10 UI/L. Statistical analysis revealed a negative response to vaccination in patients with Crohn's disease and immunosuppressive drugs.
The success rate of HBV immunization in IBD patients is low compared to the general population. Type of disease and use of immunosuppressive drugs appear to influence the vaccine response.
炎症性肠病（IBD）患者接种乙型肝炎疫苗后，达到保护性抗体水平的成功率较低。对此提出的主要因素是IBD本身以及免疫抑制药物的使用。
评估IBD患者中抗-HBs抗体的浓度，并验证与乙型肝炎疫苗接种效果相关的因素。
这是一项前瞻性、连续性、观察性、描述性和分析性、非随机的定性研究，评估了圣卡塔琳娜州伊塔雅伊市UNIVALI家庭与社区健康单位跨学科炎症性肠病诊所中IBD患者的抗-HBs抗体水平。
36名患者接种了乙型肝炎病毒（HBV）疫苗，其中29名女性。平均年龄为46.2岁。关于IBD类型，24名患者患有克罗恩病，炎症性肠病病程为74个月。15名患者正在接受联合免疫抑制治疗。通过抗-HBs滴定≥10 UI/L验证，对HBV疫苗的有效反应率为72.2%。统计分析显示，克罗恩病患者和使用免疫抑制药物的患者对疫苗接种反应为阴性。
与普通人群相比，IBD患者中HBV免疫接种的成功率较低。疾病类型和免疫抑制药物的使用似乎会影响疫苗反应。
